Bill Text: TX HB595 | 2015-2016 | 84th Legislature | Comm Sub
Bill Title: Relating to the addition of certain substances to Penalty Groups 1-A and 2 of the Texas Controlled Substances Act for criminal prosecution and other purposes.
Sponsorship: Moderate Partisan Bill (Republican 7-2)
Status: (Introduced - Dead) 2015-05-08 - Laid on the table subject to call [HB595 Detail]
Download: Texas-2015-HB595-Comm_Sub.html
| 84R8342 GCB-F | |||
| By: Clardy, Price, Turner of Tarrant, | H.B. No. 595 | ||
| Villalba, Metcalf, et al. | |||
| Substitute the following for H.B. No. 595: | |||
| By: Herrero | C.S.H.B. No. 595 | ||
|
|
||
|
|
||
| relating to the addition of certain substances to Penalty Groups | ||
| 1-A and 2 of the Texas Controlled Substances Act for criminal | ||
| prosecution and other purposes. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Section 481.002(50), Health and Safety Code, is | ||
| amended to read as follows: | ||
| (50) "Abuse unit" means: | ||
| (A) except as provided by Paragraph (B): | ||
| (i) a single unit on or in any adulterant, | ||
| dilutant, or similar carrier medium, including marked or perforated | ||
| blotter paper, a tablet, gelatin wafer, sugar cube, or stamp, or | ||
| other medium that contains any amount of a controlled substance | ||
| listed in Penalty Group 1-A, if the unit is commonly used in abuse | ||
| of that substance; or | ||
| (ii) each quarter-inch square section of | ||
| paper, if the adulterant, dilutant, or carrier medium is paper not | ||
| marked or perforated into individual abuse units; or | ||
| (B) if the controlled substance is in liquid or | ||
| solid form, 40 micrograms of the controlled substance including any | ||
| adulterant or dilutant. | ||
| SECTION 2. Section 481.1021, Health and Safety Code, is | ||
| amended to read as follows: | ||
| Sec. 481.1021. PENALTY GROUP 1-A. (a) Penalty Group 1-A | ||
| consists of: | ||
| (1) lysergic acid diethylamide (LSD), including its | ||
| salts, isomers, and salts of isomers; and | ||
| (2) compounds structurally derived from | ||
| 2,5-dimethoxyphenethylamine by substitution at the 1-amino | ||
| nitrogen atom with a benzyl substituent, including: | ||
| (A) compounds further modified by: | ||
| (i) substitution in the phenethylamine ring | ||
| at the 4- position to any extent (including alkyl, alkoxy, | ||
| alkylenedioxy, haloalkyl, or halide substituents); or | ||
| (ii) substitution in the benzyl ring to any | ||
| extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or | ||
| halide substituents); and | ||
| (B) by example, compounds such as: | ||
| 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzyl) | ||
| phenethylamine (trade or other names: 25B-NBOMe, 2C-B-NBOMe); | ||
| 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl) | ||
| phenethylamine (trade or other names: 25C-NBOMe, 2C-C-NBOMe); | ||
| 2,5-Dimethoxy-4-methyl-N-(2-methoxybenzyl) | ||
| phenethylamine (trade or other names: 25D-NBOMe, 2C-D-NBOMe); | ||
| 4-Ethyl-2,5-dimethoxy-N-(2-methoxybenzyl) | ||
| phenethylamine (trade or other names: 25E-NBOMe, 2C-E-NBOMe); | ||
| 2,5-Dimethoxy-N-(2- | ||
| methoxybenzyl)phenethylamine (some trade and other names: | ||
| 25H-NBOMe, 2C-H-NBOMe); | ||
| 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl) | ||
| phenethylamine (some trade and other names: 25I-NBOMe, | ||
| 2C-I-NBOMe); | ||
| 4-Iodo-2,5-dimethoxy-N- | ||
| benzylphenethylamine (trade or other name: 25I-NB); | ||
| 4-Iodo-2,5-dimethoxy-N-(2,3- | ||
| methylenedioxybenzyl)phenethylamine (trade or other name: | ||
| 25I-NBMD); | ||
| 4-Iodo-2,5-dimethoxy-N-(2- | ||
| fluorobenzyl)phenethylamine (trade or other name: 25I-NBF); | ||
| 4-Iodo-2,5-dimethoxy-N-(2-hydroxybenzyl) | ||
| phenethylamine (trade or other name: 25I-NBOH); | ||
| 2,5-Dimethoxy-4-nitro-N-(2-methoxybenzyl) | ||
| phenethylamine (trade or other names: 25N-NBOMe, 2C-N-NBOMe); and | ||
| 2,5-Dimethoxy-4-(n)-propyl-N-(2- | ||
| methoxybenzyl)phenethylamine (some trade and other names: | ||
| 25P-NBOMe, 2C-P-NBOMe). | ||
| (b) To the extent Subsection (a)(2) conflicts with another | ||
| provision of this subtitle or another law, the other provision or | ||
| the other law prevails. | ||
| SECTION 3. Section 481.103, Health and Safety Code, is | ||
| amended by amending Subsections (a) and (c) and adding Subsection | ||
| (d) to read as follows: | ||
| (a) Penalty Group 2 consists of: | ||
| (1) any quantity of the following hallucinogenic | ||
| substances, their salts, isomers, and salts of isomers, unless | ||
| specifically excepted, if the existence of these salts, isomers, | ||
| and salts of isomers is possible within the specific chemical | ||
| designation: | ||
| 5-(2-aminopropyl)benzofuran (5-APB); | ||
| 6-(2-aminopropyl)benzofuran (6-APB); | ||
| 5-(2-aminopropyl)-2,3-dihydrobenzofuran | ||
| (5-APDB); | ||
| 6-(2-aminopropyl)-2,3-dihydrobenzofuran | ||
| (6-APDB); | ||
| 5-(2-aminopropyl)indole (5-IT,5-API); | ||
| 6-(2-aminopropyl)indole (6-IT,6-API); | ||
| 1-(benzofuran-5-yl)-N-methylpropan-2-amine | ||
| (5-MAPB); | ||
| 1-(benzofuran-6-yl)-N-methylpropan-2-amine | ||
| (6-MAPB); | ||
| Benzothiophenylcyclohexylpiperidine (BTCP); | ||
| 8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- | ||
| 4-ethanamine (trade or other name: Bromo-DragonFLY); | ||
| Desoxypipradrol (2-benzhydrylpiperidine); | ||
| [ |
||
| [ |
||
| [ |
||
|
|
||
|
|
||
| [ |
||
| [ |
||
|
|
||
|
|
||
|
|
||
| [ |
||
|
|
||
| 2, 5-dimethoxyamphetamine (some trade or other | ||
| names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA); | ||
| Diphenylprolinol (diphenyl(pyrrolidin-2-yl) | ||
| methanol, D2PM); | ||
| [ |
||
|
|
||
| [ |
||
|
|
||
| [ |
||
| Dronabinol (synthetic) in sesame oil and | ||
| encapsulated in a soft gelatin capsule in a U.S. Food and Drug | ||
| Administration approved drug product (some trade or other names for | ||
| Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- | ||
| trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- | ||
| (trans)- tetrahydrocannabinol); | ||
| Ethylamine Analog of Phencyclidine (some trade or | ||
| other names: N-ethyl-1-phenylcyclohexylamine, (1- | ||
| phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, | ||
| cyclohexamine, PCE); | ||
| 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone | ||
| (trade or other name: methoxetamine); | ||
| Ibogaine (some trade or other names: 7-Ethyl-6, | ||
| 6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- | ||
| pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.); | ||
| 5-iodo-2-aminoindane (5-IAI); | ||
| Mescaline; | ||
| [ |
||
| 5-methoxy-3, 4-methylenedioxy amphetamine; | ||
| 4-methoxyamphetamine (some trade or other | ||
| names: 4-methoxy-alpha-methylphenethylamine; | ||
| paramethoxyamphetamine; PMA); | ||
| 4-methoxymethamphetamine (PMMA); | ||
| 2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone | ||
| (some trade and other names: 2-MeO-ketamine; methoxyketamine); | ||
| 1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, | ||
| PPMP); | ||
| 4-methyl-2, 5-dimethoxyamphetamine (some trade | ||
| and other names: 4-methyl-2, 5-dimethoxy-alpha- | ||
| methylphenethylamine; "DOM"; "STP"); | ||
| 3,4-methylenedioxy methamphetamine (MDMA, MDM); | ||
| 3,4-methylenedioxy amphetamine; | ||
| 3,4-methylenedioxy N-ethylamphetamine (Also | ||
| known as N-ethyl MDA); | ||
| 5,6-methylenedioxy-2-aminoindane (MDAI); | ||
| Nabilone (Another name for nabilone: (+)-trans- | ||
| 3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, | ||
| 6-dimethyl-9H-dibenzo[b,d] pyran-9-one; | ||
| N-benzylpiperazine (some trade or other | ||
| names: BZP; 1-benzylpiperazine); | ||
| N-ethyl-3-piperidyl benzilate; | ||
| N-hydroxy-3,4-methylenedioxyamphetamine (Also | ||
| known as N-hydroxy MDA); | ||
| 4-methylaminorex; | ||
| N-methyl-3-piperidyl benzilate; | ||
| Parahexyl (some trade or other names: 3-Hexyl-1- | ||
| hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] | ||
| pyran; Synhexyl); | ||
| 1-Phenylcyclohexylamine; | ||
| 1-Piperidinocyclohexanecarbonitrile (PCC); | ||
| [ |
||
| [ |
||
| Pyrrolidine Analog of Phencyclidine (some trade | ||
| or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP); | ||
| Tetrahydrocannabinols, other than marihuana, and | ||
| synthetic equivalents of the substances contained in the plant, or | ||
| in the resinous extractives of Cannabis, or synthetic substances, | ||
| derivatives, and their isomers with similar chemical structure and | ||
| pharmacological activity such as: | ||
| delta-1 cis or trans tetrahydrocannabinol, | ||
| and their optical isomers; | ||
| delta-6 cis or trans tetrahydrocannabinol, | ||
| and their optical isomers; | ||
| delta-3, 4 cis or trans | ||
| tetrahydrocannabinol, and its optical isomers; or | ||
| compounds of these structures, regardless of | ||
| numerical designation of atomic positions, since nomenclature of | ||
| these substances is not internationally standardized; | ||
| Thiophene Analog of Phencyclidine (some trade or | ||
| other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl | ||
| Analog of Phencyclidine; TPCP, TCP); | ||
| 1-pyrrolidine (some trade or other name: TCPy); | ||
| 1-(3-trifluoromethylphenyl)piperazine (trade or | ||
| other name: TFMPP); and | ||
| 3,4,5-trimethoxy amphetamine; | ||
| (2) Phenylacetone (some trade or other | ||
| names: Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl | ||
| ketone); | ||
| (3) unless specifically excepted or unless listed in | ||
| another Penalty Group, a material, compound, mixture, or | ||
| preparation that contains any quantity of the following substances | ||
| having a potential for abuse associated with a depressant or | ||
| stimulant effect on the central nervous system: | ||
| Aminorex (some trade or other | ||
| names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5- | ||
| phenyl-2-oxazolamine); | ||
| Amphetamine, its salts, optical isomers, and | ||
| salts of optical isomers; | ||
| Cathinone (some trade or other names: 2-amino-1- | ||
| phenyl-1-propanone, alpha-aminopropiophenone, 2- | ||
| aminopropiophenone); | ||
| Etaqualone and its salts; | ||
| Etorphine Hydrochloride; | ||
| Fenethylline and its salts; | ||
| Lisdexamfetamine, including its salts, isomers, | ||
| and salts of isomers; | ||
| Mecloqualone and its salts; | ||
| Methaqualone and its salts; | ||
| Methcathinone (some trade or other names: 2- | ||
| methylamino-propiophenone; alpha-(methylamino)propriophenone; | ||
| 2-(methylamino)-1-phenylpropan-1-one; alpha-N- | ||
| methylaminopropriophenone; monomethylpropion; ephedrone, N- | ||
| methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR | ||
| 1431); | ||
| N-Ethylamphetamine, its salts, optical isomers, | ||
| and salts of optical isomers; and | ||
| N,N-dimethylamphetamine (some trade or other | ||
| names: N,N,alpha-trimethylbenzeneethanamine | ||
| [ |
||
| N,N,alpha-trimethylphenethylamine), its salts, optical isomers, | ||
| and salts of optical isomers; [ |
||
| (4) any compound structurally derived from | ||
| 2-aminopropanal by substitution at the 1-position with any | ||
| monocyclic or fused-polycyclic ring system, including: | ||
| (A) compounds further modified by: | ||
| (i) substitution in the ring system to any | ||
| extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or | ||
| halide substituents), whether or not further substituted in the | ||
| ring system by other substituents; | ||
| (ii) substitution at the 3-position with an | ||
| alkyl substituent; or | ||
| (iii) substitution at the 2-amino nitrogen | ||
| atom with alkyl, benzyl, [ |
||
| inclusion of the 2-amino nitrogen atom in a cyclic structure; and | ||
| (B) by example, compounds such as: | ||
| 4-Methylmethcathinone (Also known as | ||
| Mephedrone); | ||
| 3,4-Dimethylmethcathinone (Also known as | ||
| 3,4-DMMC); | ||
| 3-Fluoromethcathinone (Also known as 3-FMC); | ||
| 4-Fluoromethcathinone (Also known as | ||
| Flephedrone); | ||
| 3,4-Methylenedioxy-N-methylcathinone (Also | ||
| known as Methylone); | ||
| 3,4-Methylenedioxypyrovalerone (Also known | ||
| as MDPV); | ||
| alpha-Pyrrolidinopentiophenone (Also known | ||
| as alpha-PVP); | ||
| Naphthylpyrovalerone (Also known as | ||
| Naphyrone); | ||
| alpha-Methylamino-valerophenone (Also known | ||
| as Pentedrone); | ||
| beta-Keto-N-methylbenzodioxolylpropylamine | ||
| (Also known as Butylone); | ||
| beta-Keto-N-methylbenzodioxolylpentanamine | ||
| (Also known as Pentylone); | ||
| beta-Keto-Ethylbenzodioxolylbutanamine | ||
| (Also known as Eutylone); and | ||
| 3,4-methylenedioxy-N-ethylcathinone (Also | ||
| known as Ethylone); | ||
| (5) any compound structurally derived from tryptamine | ||
| (3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine: | ||
| (A) by modification in any of the following ways: | ||
| (i) by substitution at the amine nitrogen | ||
| atom of the sidechain to any extent with alkyl or alkenyl groups or | ||
| by inclusion of the amine nitrogen atom of the side chain (and no | ||
| other atoms of the side chain) in a cyclic structure; | ||
| (ii) by substitution at the carbon atom | ||
| adjacent to the nitrogen atom of the side chain (alpha-position) | ||
| with an alkyl or alkenyl group; | ||
| (iii) by substitution in the 6-membered | ||
| ring to any extent with alkyl, alkoxy, haloalkyl, thioaklyl, | ||
| alkylenedioxy, or halide substituents; or | ||
| (iv) by substitution at the 2-position of | ||
| the tryptamine ring system with an alkyl substituent; and | ||
| (B) including: | ||
| (i) ethers and esters of the controlled | ||
| substances listed in this subdivision; and | ||
| (ii) by example, compounds such as: | ||
| alpha-ethyltryptamine; | ||
| alpha-methyltryptamine; | ||
| Bufotenine (some trade and other names: | ||
| 3-(beta- Dimethylaminoethyl)-5-hydroxyindole; | ||
| 3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; | ||
| 5-hydroxy-N, N- dimethyltryptamine; mappine); | ||
| Diethyltryptamine (some trade and | ||
| other names: N, N-Diethyltryptamine, DET); | ||
| Dimethyltryptamine (trade or other | ||
| name: DMT); | ||
| 5-methoxy-N, N-diisopropyltryptamine | ||
| (5-MeO-DiPT); | ||
| O-Acetylpsilocin (Trade or other name: | ||
| 4-Aco-DMT); | ||
| Psilocin; and | ||
| Psilocybin; | ||
| (6) 2,5-Dimethoxyphenethylamine and any compound | ||
| structurally derived from 2,5-Dimethoxyphenethylamine by | ||
| substitution at the 4-position of the phenyl ring to any extent | ||
| (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide | ||
| substituents), including, by example, compounds such as: | ||
| 4-Bromo-2,5-dimethoxyphenethylamine (trade or | ||
| other name: 2C-B); | ||
| 4-Chloro-2,5-dimethoxyphenethylamine (trade or | ||
| other name: 2C-C); | ||
| 2,5-Dimethoxy-4-methylphenethylamine (trade or | ||
| other name: 2C-D); | ||
| 4-Ethyl-2,5-dimethoxyphenethylamine (trade or | ||
| other name: 2C-E); | ||
| 4-Iodo-2,5-dimethoxyphenethylamine (trade or | ||
| other name: 2C-I); | ||
| 2,5-Dimethoxy-4-nitrophenethylamine (trade or | ||
| other name: 2C-N); | ||
| 2,5-Dimethoxy-4-(n)-propylphenethylamine (trade | ||
| or other name: 2C-P); | ||
| 4-Ethylthio-2,5-dimethoxyphenethylamine (trade | ||
| or other name: 2C-T-2); | ||
| 4-Isopropylthio-2,5-dimethoxyphenethylamine | ||
| (trade or other name: 2C-T-4); and | ||
| 2,5-Dimethoxy-4-(n)-propylthiophenethylamine | ||
| (trade or other name: 2C-T-7); and | ||
| (7) 2,5-Dimethoxyamphetamine and any compound | ||
| structurally derived from 2,5-Dimethoxyamphetamine by substitution | ||
| at the 4-position of the phenyl ring to any extent (including alkyl, | ||
| alkoxy, alkylenedioxy, haloalkyl, or halide substituents), | ||
| including, by example, compounds such as: | ||
| 4-Ethylthio-2,5-dimethoxyamphetamine (trade or | ||
| other name: Aleph-2); | ||
| 4-Isopropylthio-2,5-dimethoxyamphetamine (trade | ||
| or other name: Aleph-4); | ||
| 4-Bromo-2,5-dimethoxyamphetamine (trade or other | ||
| name: DOB); | ||
| 4-Chloro-2,5-dimethoxyamphetamine (trade or | ||
| other name: DOC); | ||
| 2,5-Dimethoxy-4-ethylamphetamine (trade or other | ||
| name: DOET); | ||
| 4-Iodo-2,5-dimethoxyamphetamine (trade or other | ||
| name: DOI); | ||
| 2,5-Dimethoxy-4-methylamphetamine (trade or | ||
| other name: DOM); | ||
| 2,5-Dimethoxy-4-nitroamphetamine (trade or other | ||
| name: DON); | ||
| 4-Isopropyl-2,5-dimethoxyamphetamine (trade or | ||
| other name: DOIP); and | ||
| 2,5-Dimethoxy-4-(n)-propylamphetamine (trade or | ||
| other name: DOPR). | ||
| (c) To the extent Subsection (a)(4), (5), (6), or (7) | ||
| conflicts with another provision or this subtitle or another law, | ||
| the other provision [ |
||
| substance listed in this section is also listed in another penalty | ||
| group, the listing in the other penalty group controls. | ||
| (d) If a substance listed in this section is approved by the | ||
| Federal Drug Administration, the inclusion of that substance in | ||
| this penalty group does not apply, and notwithstanding any other | ||
| law, a person may not be convicted for the manufacture or delivery | ||
| of the substance under Section 481.113 or for possession of the | ||
| substance under Section 481.116. | ||
| SECTION 4. The change in law made by this Act applies only | ||
| to an offense committed on or after the effective date of this Act. | ||
| An offense committed before the effective date of this Act is | ||
| governed by the law in effect on the date the offense was committed, | ||
| and the former law is continued in effect for that purpose. For | ||
| purposes of this section, an offense was committed before the | ||
| effective date of this Act if any element of the offense occurred | ||
| before that date. | ||
| SECTION 5. This Act takes effect September 1, 2015. | ||
